New MDMA variants could be promising alternatives for safe psychotherapeutic applications

FHS
June 25, 2024
3:05 pm

The use of the active ingredient 3,4-methylenedioxy-N-methylamphetamine (MDMA), commonly known as “ecstasy”, to support psychotherapy for mental illnesses such as post-traumatic stress disorder is being discussed worldwide.

Boston Scientific wins FDA approval for Farapulse cardiac mapping

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Boston Scientific received Food and

October 21, 2024

How Clinicians Can Brush Up on Emerging Schizophrenia Drugs

At the recent Psych Congress 2023, a session titled “State of the Science: Focus on Schizophrenia” was presented by Peter Weiden, MD, a clinical professor

October 11, 2023

From Dr. Oz to heart valves: A tiny device charted a contentious path through the FDA

In 2013, the FDA approved an implantable device to treat leaky heart valves. Among its inventors was Mehmet Oz, the former television personality and former

July 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.